Massimo Federico MD

Massimo Federico is a Professor of Medical Oncology at the University of Modena and Reggio Emilia, Modena, Italy, and an Advisor of the Lymphoma Unit at Modena Cancer Center. Professor Federico has been the president of Gruppo Italiano Studio Linfomi (GISL) and thereafter of Fondazione Italiana Linfomi (FIL). He is currently President of the AIBE (Associazione Italo Brasiliana di Ematologia), and Co-Chairman of the Lymphomahub, a global online platform whose vision is to provide up-to-date, practical, clinical advice to community hem-oncologists, hematologists, and oncologists seeking treatment and management options for Lymphoma and CLL

He is the author or co-author of more than 400 peer-reviewed publications. Professor Federico has designed and conducted several phases II and III clinical trials in different subtypes of Hodgkin's and non-Hodgkin’s lymphoma. Moreover, has widely investigated the role of prognostic factors in different lymphomas, including Hodgkin, Follicular, and Peripheral T Cell Lymphomas.

He is currently leading the T Cell Project and the Aristotle Study, a project on the incidence and outcome of transformed Follicular Lymphoma in the Rituximab era promoted by the European Lymphoma Institute and the EHA Lymphoma Group.